Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

FDA Issues Boxed Warning for Denosumab & Approves a Generic NSAID

  |  Issue: April 2024  |  

References

  1. Prolia (denosumab): Drug safety communication—FDA adds boxed warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease. U.S. Food & Drug Administration. 2024 Jan 19.
  2. Biologics license application approval: Prolia (denosumab). U.S. Food & Drug Administration. 2010 Jun 1.
  3. Highlights of prescribing information: Prolia (denosumab). U.S. Food & Drug Administration. 2024 Jan 19.
  4. News release: ANI Pharmaceuticals announces FDA approval and launch of indomethacin oral suspension. ANI Pharmaceuticals Inc. 2024 Jan 16.
  5. Highlights of prescribing information: Indocin (indomethacin) oral suspension. U.S. Food & Drug Administration. 2021 Apr 28.

Related Articles

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    Psoriatic Arthritis Drugs at a Glance, 2023

    Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…